What non‑narcotic, non‑addictive treatments can be prescribed for a 69‑year‑old woman with insomnia who is currently taking nightly 5 mg zolpidem?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Non-Narcotic, Non-Addictive Treatment Options for Insomnia in a 69-Year-Old Woman

For this 69-year-old woman currently on zolpidem, the strongest evidence-based non-narcotic, non-addictive option is cognitive behavioral therapy for insomnia (CBT-I), which should be initiated as first-line treatment. 1 If pharmacologic therapy is needed, ramelteon (melatonin receptor agonist), low-dose doxepin, or dual orexin receptor antagonists (DORAs) are non-addictive alternatives. 1, 2

First-Line Treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I)

The 2016 American College of Physicians guideline explicitly recommends CBT-I as the initial treatment for chronic insomnia in all adults, including older patients. 1 This is a multicomponent behavioral approach that includes:

  • Stimulus control: Use bedroom only for sleep and sex; leave bedroom if unable to fall asleep within 15-20 minutes 2
  • Sleep restriction: Limit time in bed to actual sleep time, then gradually increase
  • Sleep hygiene education: Maintain consistent bed/wake times; avoid caffeine, nicotine, alcohol; no heavy exercise within 2 hours of bedtime 2
  • Relaxation therapy: Progressive muscle relaxation, guided imagery, diaphragmatic breathing 2
  • Cognitive therapy: Address misperceptions about sleep needs in aging

CBT-I has demonstrated sustained long-term benefits beyond medication alone and carries no risk of dependence or adverse effects. 2

Non-Addictive Pharmacologic Options

When behavioral therapy alone is insufficient, the following FDA-approved medications have no evidence of abuse potential or dependence:

Ramelteon (Melatonin Receptor Agonist)

  • Mechanism: Acts on melatonin receptors involved in circadian rhythm regulation 2
  • Key advantage: No significant effects indicative of abuse potential, motor impairment, or cognitive impairment 2
  • Best for: Sleep-onset insomnia 3
  • Elderly dosing: Start at lowest dose

Low-Dose Doxepin (3-6 mg)

  • FDA-approved for insomnia at low doses 1
  • Best for: Sleep maintenance problems 3
  • Note: This is distinct from higher antidepressant doses; at low doses it acts as a histamine antagonist

Dual Orexin Receptor Antagonists (DORAs)

  • Agents: Suvorexant, lemborexant, daridorexant 1, 4
  • Mechanism: Inhibit wakefulness rather than induce sedation 4
  • Key advantages: No evidence of rebound insomnia, withdrawal, or abuse potential 4
  • Best for: Sleep maintenance 3
  • Daridorexant: Newest agent with ideal 8-hour half-life and demonstrated 12-month efficacy 4

Critical Context: Zolpidem Concerns in Elderly

The patient's current medication (zolpidem 5 mg) is a benzodiazepine receptor agonist with significant concerns in elderly patients:

  • Increased fall risk and injuries 5
  • Potential increased mortality 5
  • Next-day cognitive impairment documented in elderly 6
  • Memory impairment (anterograde amnesia) at doses ≥10 mg 6
  • FDA-approved only for short-term use (4-5 weeks) 6
  • Rebound insomnia documented in elderly at doses >5 mg 6

Recommended Treatment Algorithm

  1. Initiate CBT-I immediately as primary treatment 1

  2. If pharmacologic therapy needed concurrently or CBT-I unavailable:

    • For sleep-onset insomnia: Ramelteon 3
    • For sleep maintenance: Suvorexant, lemborexant, or daridorexant 3
    • For both onset and maintenance: Low-dose doxepin 3
  3. Gradual zolpidem discontinuation (if switching):

    • Reduce dose by 10-25% weekly 7
    • Consider cross-tapering with daridorexant or melatonin 2 mg prolonged-release 7
    • CBT-I facilitates discontinuation 7

Options to Avoid

  • Benzodiazepines: High risk of adverse effects in elderly, should not be used routinely 2, 3
  • Antihistamines (diphenhydramine): Not recommended; anticholinergic effects problematic in elderly 3
  • Trazodone: Despite common off-label use, carries significant risks and limited efficacy data 3
  • Antipsychotics: Not recommended for insomnia 3

Common Pitfalls

  • Continuing zolpidem long-term beyond 4-5 weeks without reassessment 6
  • Failing to address underlying sleep hygiene and behavioral factors 2
  • Using higher doses in elderly (zolpidem >5 mg increases adverse effects) 6
  • Prescribing sedating medications without considering fall risk in this age group 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.